SHANGHAI FUDAN H YC-,10 Total Liabilities
SHANGHAI FUDAN H YC-,10 total liabilities. Based on the latest financial reports, SHANGHAI FUDAN H YC-,10 (FDY) has total liabilities worth €260.40 Million EUR (≈ $304.44 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check FDY asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SHANGHAI FUDAN H YC-,10 (2021–2025)
Total liabilities of SHANGHAI FUDAN H YC-,10 from 2021 to 2025. This chart illustrates how SHANGHAI FUDAN H YC-,10's total liabilities have evolved over time, based on quarterly financial data.
SHANGHAI FUDAN H YC-,10 Competitors by Total Liabilities
The table below lists competitors of SHANGHAI FUDAN H YC-,10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HLS Therapeutics Inc
TO:HLS
|
Canada | CA$75.72 Million |
|
Thuan Duc JSC
VN:TDP
|
Vietnam | ₫3.36 Trillion |
|
Seosan Corporation
KQ:079650
|
Korea | ₩5.50 Billion |
|
Skillz Platform Inc
NYSE:SKLZ
|
USA | $190.27 Million |
|
Kestrel Group, Ltd.
NYSE:KG
|
USA | $986.67 Million |
|
VenueG Co. Ltd
KQ:019010
|
Korea | ₩338.16 Billion |
|
Lemonsoft Oyj
HE:LEMON
|
Finland | €21.66 Million |
|
Sedana Medical AB
ST:SEDANA
|
Sweden | Skr49.06 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SHANGHAI FUDAN H YC-,10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see FDY total asset value.
Liquidity & Leverage Metrics
SHANGHAI FUDAN H YC-,10 Total Liabilities Ratios Explained
SHANGHAI FUDAN H YC-,10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANGHAI FUDAN H YC-,10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANGHAI FUDAN H YC-,10 (2021–2025)
The table below shows the annual total liabilities of SHANGHAI FUDAN H YC-,10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €273.93 Million ≈ $320.26 Million |
-2.59% |
| 2024-12-31 | €281.23 Million ≈ $328.78 Million |
-45.72% |
| 2023-12-31 | €518.12 Million ≈ $605.74 Million |
-28.34% |
| 2022-12-31 | €722.99 Million ≈ $845.25 Million |
+22.21% |
| 2021-12-31 | €591.58 Million ≈ $691.62 Million |
-- |
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more